SynthesisNoise & health
A Systematic Review of the Effectiveness of Hydrogen Therapy in Hearing Loss.
Synthesis in Noise & health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHydrogen (H 2 ) therapy demonstrates selective antioxidant and anti-inflammatory properties with potential therapeutic value for multiple forms of hearing loss, though consolidated evidence is still lacking.
methodsWe conducted a systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, searching PubMed, MEDLINE, and DOAJ (until March 1, 2025) for studies on H 2 treatment for noise-induced hearing loss (NIHL), drug-induced hearing loss (DIHL), radiotherapy-induced hearing loss (RIHL), and idiopathic sudden sensorineural hearing loss (ISSNHL). After screening by two reviewers, 11 studies involving human or animal subjects were included. Data were synthesized by hearing loss type, and the Systematic Review Centre for Laboratory Animal Experimentation tool assessed bias risk in animal studies.
resultsIn NIHL models, H 2 administration reduced Auditory Brainstem Response threshold shifts and improved Distortion Product Otoacoustic Emissions recovery, while preserving cochlear morphology via reactive oxygen species (ROS) suppression. For DIHL, inhaled H 2 protected hair cells and spiral ganglion neurons through ROS scavenging and apoptosis inhibition. Clinically, H 2 inhalation improved hearing in RIHL patients post-radiotherapy. One randomized trial in ISSNHL showed H 2 combined with standard therapy significantly enhanced hearing recovery.
conclusionH 2 exhibits protective effects in preclinical NIHL and DIHL models, and promising outcomes in clinical RIHL and ISSNHL, primarily via antioxidative and anti-inflammatory mechanisms. Further trials are required to establish optimal protocols and confirm efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.